Ligand Boosts Royalties 56% in Q1 2026, Eyes XOMA Acquisition
Event summary
- Ligand reported a 56% year-over-year increase in royalty revenue for Q1 2026, driven by strong performance from Filspari and other key assets.
- The company reaffirmed its raised 2026 financial guidance, anticipating a partial-year contribution from the pending XOMA Royalty acquisition.
- XOMA acquisition will add over 120 commercial, clinical, and preclinical-stage assets to Ligand’s portfolio, diversifying across therapeutic areas and stages of development.
- Filspari received full FDA approval for treating FSGS, expanding its market beyond IgA nephropathy.
- Ligand’s adjusted net income grew 30% year-over-year to $34.6 million, or $1.63 per diluted share.
The big picture
Ligand’s strong Q1 2026 performance underscores the strategic value of its royalty aggregation model, particularly in the biotech sector. The pending XOMA acquisition positions the company to further diversify its portfolio, mitigating reliance on any single asset or therapeutic area. The FDA approval of Filspari for FSGS highlights the potential for Ligand’s royalties to drive long-term growth, especially as the company continues to invest in high-value royalty assets.
What we're watching
- Integration Challenges
- The pace at which Ligand can integrate XOMA’s portfolio and realize anticipated cost synergies will be critical to meeting its raised guidance.
- Regulatory Momentum
- The FDA approval of Filspari for FSGS and the progress of Qtorin rapamycin through clinical trials will shape Ligand’s long-term royalty growth.
- Market Expansion
- How Ligand leverages its diversified portfolio to expand into new therapeutic areas and sustain revenue growth beyond its current key assets.
Related topics